Adverse Effects of GLP-1 Drugs: What Physicians Should Know

Just a couple of years after some TikTok videos surged the need, one in 8 US adults has actually attempted Ozempic (semaglutide) or another drug in its class. Glucagon-like peptide 1 (GLP-1) receptor agonist medications have revolutionized obesity medicine.But they’re not without problems. In the early days of the social networks fad, report often included patients whose intestinal side effects sent them to the emergency room (ER).”It happened a lot then.

Patients didn’t wish to grumble since they were slimming down, and they wound up in the ER with extreme irregularity or a small bowel obstruction,” said Caroline Apovian, MD, co-director of the Center for Weight Management and Wellness at Brigham and Women’s Hospital and teacher of medicine at Harvard Medical School, Boston.

Caroline Apovian, MD”But that’s not actually taking place now,” she added.Research backs up her

assertion: A recent medical evaluation of research studies found that lots of clients still experience negative effects, but just at a moderate to moderate level, while the dose increases– and the unpleasantness tapers with time. Approximately 7 %of patients cease the medications due to these symptoms.Here’s what the most recent research reveals about GLP-1s’side effects.Most Common: Intestinal Issues Depending upon the sign and the specific drug, anywhere from one third

to one half of patients will experience some kind

of stomach trouble.In that scientific evaluation, which looked at studies of three GLP-1 medications– semaglutide (Ozempic, Wegovy, Rybelsus ), liraglutide (Saxenda, Victoza

• ), and tirzepatide (Mounjaro, Zepbound)– semaglutide users fared relatively worse.Nausea was reported most regularly– 44.2% of semaglutide users handled it, compared with 40.2%for liraglutide and 31 %for tirzepatide. Diarrhea, irregularity, and throwing up likewise struck one
• quarter to one third of semaglutide patients, and somewhat less for the other two medications.Apovian finds that mindful dose helps her clients avoid the worst impacts. “We do not know who’s going to do well and who’s not,”she said. “We start gradually, and normally things go OK.”If a patient does respond poorly, she’ll hold back on increasing the dose till they adapt and encourage utilizing non-prescription medications like MiraLAX to deal with the symptoms.Few recorded serious negative gastro events appeared in the information, impacting less than 1%of liraglutide and tirzepatide

  clients and 2.6%of semaglutide users. Most of these events were gallbladder-related. Concerns About Causation: Depression and Suicidality About a year ago, a research study utilized 18 years’worth

  of information from the US Fda(FDA )Unfavorable Occasion Reporting System(FAERS) to examine how frequently clients reported self-destructive ideation and/or depression while using GLP-1 medications. Compared to metformin and insulin, researchers discovered out of proportion reporting by patients using semaglutide and liraglutide. Other GLP-1 medications didn’t show this impact. The scientists explained: These stats do not reveal causation– there’s no clear reason why those 2 medications were linked to more reports.Further research has been more comforting: Another study also utilized FAERS but looked just at data from 2018 to 2022, when use of these drugs was ramping up, and found no link in between suicidal or self-injurious habits and GLP-1. A current mate study, which looked at information from almost 300,000 people, found that GLP-1 users aren’t at increased danger for death by suicide.Both the FDA and the European Medicines Company have provided statements that the evidence does not support a causal association.There are several

• elements at play here. People with weight problems and diabetes are most likely to have anxiety to start with. And more notably, even if there is a link, causality remains unclear. For example, patients who reduce weight through bariatric surgical treatment are at increased danger for depression, substance abuse, and self-harm. These signs may be connected to the weight reduction itself, not the medications.”Some people utilize food as something other than nutrition. They use food to soothe other psychological concerns,”Apovian said.”

When that’s removed, the psychological problems are still there.”In her practice, she’s seen the danger for psychological health problems rise with more considerable weight loss– 50-100 lb.This absence of clearness concerning causation means it is necessary to perform a comprehensive client history before prescribing, so you can keep an eye on more carefully with preexisting psychiatric disorders.Possible Link: Ocular Symptoms Here, too, the research isn’t definitive however favors no clear association

. Numerous research studies have looked for a link between GLP-1 and vision-related concerns: One taken a look at FAERS information and network pharmacology and discovered semaglutide and lixisenatide were considerably associated with adverse events like blurred vision, visual disability, and diabetic retinopathy.This summer, a friend research study of practically 17,000 people with diabetes or overweight/obesity recommended a link in between semaglutide and nonarteritic anterior ischemic optic neuropathy(NAION ), a common cause of blindness due to optic nerve damage. The research study discovered” a substantially increased risk of NAION among people prescribed semaglutide relative to those prescribed other medications to treat type 2 diabetes and obesity or obese.” But this month, another associate research study with 135,000 participants took a look at NAION

• in people with type 2 diabetes, obesity, or both. It compared outcomes with common non-GLP-1 medications and discovered simply the reverse: No increased danger for NAION.One disadvantage with all these studies is that they’re based upon large databases instead of randomized regulated trials (RCTs). When scientists concentrated on RCTs in a 2023 meta-analysis, they found a substantial association with only one kind of GLP-1, albiglutide– which was withdrawn from the market in 2017. The other six FDA-approved drugs didn’t show a statistically substantial link.Possible Problem: Lung Aspiration Under Sedation Previously this month, the FDA upgraded labeling for semaglutide, liraglutide, and tirzepatide to consist of a cautioning about the risk for goal during
• surgery. While there are no published research studies, several case reports have appeared.GLP-1 medications delay gastric emptying, so despite the fact that a client may have fasted before surgical treatment as typical, some food or liquid might stay. In action to this possibility, a group

of professional medical societies released guidelines for using these medications throughout the perioperative duration. They consist of: Consideration of dose, signs, and other medical conditions: The threat is higher during the escalation stage, and in basic, higher dosages imply greater risk.Potential discontinuation of GLP-1 use when assessment shows an elevated risk.Assessment on the day of the procedure for possible postponed gastric emptying.Preoperative dietary modifications, which might consist of switching to a liquid diet.Rare: Serious Effects And then

there are the outliers, the frightening issues that make headings. On their own, none of these prevail enough to affect consideration of GLP-1 usage: Research studies in rats suggested an increased danger for thyroid cancer, but subsequent research has actually discovered no evidence.Colonic anemia in association with tirzepatide.Acute pancreatitis resulting in death resulting in death in association with semaglutide.Speaking of pancreatitis, that scientific evaluation of studies did find that both liraglutide and semaglutide led to a raised danger for pancreatitis, bowel blockage, and gastroparesis. But the numbers were so little as to be insignificant– for